Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
China · Delayed Price · Currency is CNY 14.00
-1.53 (-9.85%)
Sep 10, 2026, 2:10 PM CST
SHE:002365 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,490 | 4,314 | 2,327 | 2,882 | 3,094 | 3,122 | |
Market Cap Growth | -15.41% | 85.39% | -19.26% | -6.86% | -0.90% | 16.11% |
Enterprise Value | 3,649 | 3,459 | 1,513 | 2,049 | 2,440 | 2,756 |
Last Close Price | 15.53 | 14.78 | 7.89 | 9.52 | 10.12 | 10.22 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 84.13 | 191.79 | 37.67 | - | 22.08 | 28.97 |
Forward PE | - | 6.36 | 6.36 | 6.36 | 6.36 | 6.36 |
PS Ratio | 4.58 | 5.51 | 2.77 | 2.96 | 2.12 | 2.00 |
PB Ratio | 2.25 | 2.18 | 1.14 | 1.41 | 1.47 | 1.60 |
P/TBV Ratio | 2.33 | 2.26 | 1.22 | 1.52 | 1.61 | 1.77 |
P/FCF Ratio | 2368.27 | 56.17 | - | 28.69 | 12.99 | 80.55 |
P/OCF Ratio | 37.42 | 31.02 | 22.01 | 13.03 | 7.99 | 30.67 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.73 | 4.42 | 1.80 | 2.11 | 1.67 | 1.76 |
EV/EBITDA Ratio | 20.34 | 31.90 | 9.90 | 12.86 | 8.31 | 11.45 |
EV/EBIT Ratio | 57.68 | - | 37.86 | 84.93 | 14.36 | 22.08 |
EV/FCF Ratio | 1924.51 | 45.04 | - | 20.39 | 10.25 | 71.09 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0 | 0 | 0.02 | 0.01 | 0.02 | 0.01 |
Debt / EBITDA Ratio | 0.00 | 0.01 | 0.26 | 0.06 | 0.14 | 0.08 |
Debt / FCF Ratio | 0.21 | 0.01 | - | 0.10 | 0.17 | 0.53 |
Net Debt / Equity Ratio | -0.42 | -0.46 | -0.43 | -0.46 | -0.38 | -0.27 |
Net Debt / EBITDA Ratio | -4.66 | -8.46 | -5.77 | -5.94 | -2.70 | -2.19 |
Net Debt / FCF Ratio | -440.72 | -11.95 | 71.45 | -9.42 | -3.33 | -13.60 |
Asset Turnover | 0.44 | 0.35 | 0.36 | 0.41 | 0.62 | 0.70 |
Inventory Turnover | 7.58 | 7.07 | 8.24 | 6.58 | 6.71 | 10.66 |
Quick Ratio | 4.71 | 5.14 | 4.38 | 4.41 | 3.60 | 3.04 |
Current Ratio | 5.25 | 5.65 | 4.83 | 4.72 | 4.19 | 3.63 |
Return on Equity (ROE) | 2.07% | 0.36% | 2.92% | -1.37% | 6.54% | 6.31% |
Return on Assets (ROA) | 1.76% | -0.23% | 1.07% | 0.63% | 4.51% | 3.51% |
Return on Invested Capital (ROIC) | 3.95% | -0.54% | 2.98% | -9.39% | 10.75% | 8.74% |
Return on Capital Employed (ROCE) | 3.20% | -0.40% | 1.90% | 1.20% | 7.90% | 6.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.19% | 0.52% | 2.65% | -0.43% | 4.54% | 3.57% |
FCF Yield | 0.04% | 1.78% | -0.53% | 3.49% | 7.70% | 1.24% |
Dividend Yield | 0.70% | 0.68% | 1.27% | 1.05% | 0.99% | - |
Payout Ratio | 108.99% | 132.85% | 48.27% | - | 1.11% | 27.59% |
Buyback Yield / Dilution | 1.00% | 1.82% | 0.52% | -0.13% | -2.66% | 0.63% |
Total Shareholder Return | 1.70% | 2.50% | 1.79% | 0.92% | -1.67% | 0.63% |